Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
28.19
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2
Open
28.19
Bid (Size)
27.00 (1)
Ask (Size)
30.00 (1)
Prev. Close
28.19
Today's Range
28.19 - 28.19
52wk Range
25.20 - 31.66
Shares Outstanding
388,132,400
Dividend Yield
2.84%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
August 16, 2024
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."
Via
Benzinga
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-0.28%
-0.28%
1 Month
-2.08%
-2.08%
3 Month
+5.82%
+5.82%
6 Month
-10.02%
-10.02%
1 Year
-7.24%
-7.24%
More News
Read More
Royalty Pharma Reports Second Quarter 2024 Results
August 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
July 24, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
NASDAQ:RPRX: good value for what you're paying.
April 24, 2024
Via
Chartmill
Royalty Pharma Declares Third Quarter 2024 Dividend
July 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
July 11, 2024
Via
Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
June 26, 2024
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
Via
InvestorPlace
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 12, 2024
Via
Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
June 05, 2024
Via
InvestorPlace
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
June 03, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
May 28, 2024
Via
Benzinga
Exposures
Product Safety
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
May 28, 2024
Via
Investor's Business Daily
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
May 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
May 23, 2024
Via
Benzinga
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024
From
Royalty Pharma plc; Cytokinetics
Via
GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
May 20, 2024
Via
InvestorPlace
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Royalty Pharma Reports First Quarter 2024 Results
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
May 02, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.